Probiotics and pidotimod face scrutiny for residual immune activation in HIV
A 2026 mini-review finds that probiotics and pidotimod remain investigational for residual immune activation in treated HIV, with heterogeneous studies ...
A 2026 mini-review finds that probiotics and pidotimod remain investigational for residual immune activation in treated HIV, with heterogeneous studies ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine